US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Emergent BioSolutions

< Previous 1 2 3 4 Next >
News headline image
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Reports First Quarter 2026 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS SABS
News headline image
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
News headline image
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
< Previous 1 2 3 4 Next >